Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced it will report business updates and financial and operating results for the third quarter of 2024 before market open on Tuesday, November 12, 2024. The company's management will host a conference call and webcast at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time on the same day to discuss developments, results, and outlook.
Investors can access the live audio webcast on Absci's investor relations website at investors.absci.com. The webcast will also be archived for later replay. This announcement indicates Absci's commitment to transparency and shareholder communication, providing an opportunity for investors to gain insights into the company's performance and future prospects.
Absci (Nasdaq: ABSI), una società di creazione di farmaci mediante IA generativa basata sui dati, ha annunciato che presenterà aggiornamenti aziendali e risultati finanziari e operativi per il terzo trimestre del 2024 prima dell'apertura del mercato il martedì 12 novembre 2024. Il management dell'azienda condurrà una chiamata in conferenza e un webcast alle 8:00 ora orientale / 5:00 ora del Pacifico lo stesso giorno per discutere sviluppi, risultati e prospettive.
Gli investitori possono accedere al webcast audio live sul sito web delle relazioni con gli investitori di Absci all'indirizzo investors.absci.com. Il webcast sarà anche archiviato per una riproduzione successiva. Questo annuncio evidenzia l'impegno di Absci per la trasparenza e la comunicazione con gli azionisti, offrendo un'opportunità agli investitori di ottenere informazioni sulle prestazioni e le prospettive future dell'azienda.
Absci (Nasdaq: ABSI), una empresa de creación de medicamentos mediante IA generativa centrada en datos, ha anunciado que informará sobre actualizaciones comerciales y resultados financieros y operativos del tercer trimestre de 2024 antes de la apertura del mercado el martes 12 de noviembre de 2024. La dirección de la empresa llevará a cabo una llamada en conferencia y un webcast a las 8:00 a.m. hora del Este / 5:00 a.m. hora del Pacífico el mismo día para discutir desarrollos, resultados y perspectivas.
Los inversores pueden acceder al webcast de audio en vivo en el sitio web de relaciones con inversores de Absci en investors.absci.com. El webcast también se archivará para su reproducción posterior. Este anuncio indica el compromiso de Absci con la transparencia y la comunicación con los accionistas, brindando una oportunidad para que los inversores obtengan información sobre el rendimiento y las perspectivas futuras de la empresa.
Absci (Nasdaq: ABSI)는 데이터 중심 생성 AI 약물 개발 회사로서 2024년 3분기 비즈니스 업데이트 및 재무 및 운영 결과를 2024년 11월 12일 화요일 시장 개장 전에 발표할 것이라고 발표했습니다. 회사 경영진은 같은 날 동부 표준시 오전 8시 / 태평양 표준시 오전 5시에 컨퍼런스 콜 및 웹캐스트를 진행하여 개발 사항, 결과 및 전망에 대해 논의할 예정입니다.
투자자는 Absci의 투자자 관계 웹사이트인 investors.absci.com에서 실시간 오디오 웹캐스트에 접근할 수 있습니다. 웹캐스트는 이후 재생을 위해 아카이브됩니다. 이 발표는 Absci가 투명성과 주주 소통에 대한 의지를 나타내며, 투자자에게 회사의 성과와 향후 전망에 대한 정보를 얻을 기회를 제공합니다.
Absci (Nasdaq: ABSI), une entreprise de création de médicaments par IA générative basée sur les données, a annoncé qu'elle publiera des mises à jour commerciales et des résultats financiers et opérationnels pour le troisième trimestre 2024 avant l'ouverture du marché le mardi 12 novembre 2024. La direction de l'entreprise organisera un appel conférence et un webcast le même jour à 8h00, heure de l'Est / 5h00, heure du Pacifique pour discuter des développements, des résultats et des perspectives.
Les investisseurs peuvent accéder au webcast audio en direct sur le site web des relations avec les investisseurs d'Absci à l'adresse investors.absci.com. Le webcast sera également archivé pour une lecture ultérieure. Cette annonce souligne l'engagement d'Absci envers la transparence et la communication avec les actionnaires, offrant ainsi aux investisseurs la possibilité d'obtenir des informations sur la performance et les perspectives futures de l'entreprise.
Absci (Nasdaq: ABSI), ein datenorientiertes Unternehmen zur Entwicklung von Medikamenten mit generativer KI, hat angekündigt, dass es Geschäftsaktualisierungen sowie finanzielle und betriebliche Ergebnisse für das dritte Quartal 2024 vor Markteröffnung am Dienstag, den 12. November 2024 bekanntgeben wird. Das Management des Unternehmens wird am selben Tag um 8:00 Uhr Eastern Time / 5:00 Uhr Pacific Time eine Konferenzschaltung und einen Webcast halten, um Entwicklungen, Ergebnisse und Ausblicke zu besprechen.
Investoren können auf den Live-Audio-Webcast über die Investor-Relations-Website von Absci zugreifen unter investors.absci.com. Der Webcast wird auch für eine spätere Wiedergabe archiviert. Diese Ankündigung unterstreicht Absci's Engagement für Transparenz und Kommunikation mit den Aktionären und bietet den Investoren die Möglichkeit, Einblicke in die Leistung und zukünftigen Perspektiven des Unternehmens zu gewinnen.
- None.
- None.
VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024.
Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating results, and outlook.
Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
When will Absci (ABSI) report its Q3 2024 financial results?
What time is Absci's (ABSI) Q3 2024 earnings conference call?
Where can I access Absci's (ABSI) Q3 2024 earnings webcast?
Will Absci's (ABSI) Q3 2024 earnings webcast be available for replay?
